Shares of Poolbeg Pharma PLC (LON:POLB – Get Free Report) traded up 2% during trading on Friday . The stock traded as high as GBX 7.79 ($0.10) and last traded at GBX 7.75 ($0.10). 1,244,478 shares changed hands during trading, a decline of 27% from the average session volume of 1,711,140 shares. The stock had previously closed at GBX 7.60 ($0.10).
Poolbeg Pharma Price Performance
The company’s fifty day simple moving average is GBX 8.55 and its 200-day simple moving average is GBX 11.31. The firm has a market capitalization of £38.75 million, a PE ratio of -775.00 and a beta of 2.11.
About Poolbeg Pharma
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- What Does a Stock Split Mean?
- Tesla Investors Continue to Profit From the Trump Trade
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Calculate Return on Investment (ROI)
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
